2305502
Project Grant
Overview
Grant Description
Sttr phase I: Steroid-eluting thread for the treatment of rhinitis - The broader impact/commercial potential of this small business technology transfer (STTR) phase I project is a novel, minimally invasive, surgical option for reducing complications and improving outcomes for rhinitis patients.
A bioabsorbable, steroid-eluting suture and surgical implant procedure will be developed to improve outcomes for 6 million patients suffering from rhinitis under the care of otolaryngologists, or ear, nose and throat specialists.
The proposed suture system and surgical suite implant procedure enables a temporary therapy that replaces the need for current chronic, daily, topical sprays and/or long-term immunotherapy with a single in-office visit.
The bioabsorbable, drug-eluting platform also provides potential extensibility for eluting other medications including antibiotic and antifungal therapies.
This small business technology transfer phase I project aims to deliver a prototype steroid-eluting dissolvable thread with an introducing surgical tool.
The project is comprised of several steps including the formulation of dissolvable polymers, and prototyping using hot melt extrusion (HME).
This effort will advance the platform design and development of optimized drug-elution thread for use in the nasal cavity.
The system will be designed using the preferred steroid of mometasone furoate and characterized for drug elution properties in a preclinical animal model.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
- Subawards are planned for this award.
A bioabsorbable, steroid-eluting suture and surgical implant procedure will be developed to improve outcomes for 6 million patients suffering from rhinitis under the care of otolaryngologists, or ear, nose and throat specialists.
The proposed suture system and surgical suite implant procedure enables a temporary therapy that replaces the need for current chronic, daily, topical sprays and/or long-term immunotherapy with a single in-office visit.
The bioabsorbable, drug-eluting platform also provides potential extensibility for eluting other medications including antibiotic and antifungal therapies.
This small business technology transfer phase I project aims to deliver a prototype steroid-eluting dissolvable thread with an introducing surgical tool.
The project is comprised of several steps including the formulation of dissolvable polymers, and prototyping using hot melt extrusion (HME).
This effort will advance the platform design and development of optimized drug-elution thread for use in the nasal cavity.
The system will be designed using the preferred steroid of mometasone furoate and characterized for drug elution properties in a preclinical animal model.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
- Subawards are planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF22551
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Jacksonville Beach,
Florida
32250-1809
United States
Geographic Scope
Single Zip Code
Related Opportunity
22-551
Simplybreathe was awarded
Project Grant 2305502
worth $255,045
from National Science Foundation in September 2023 with work to be completed primarily in Jacksonville Beach Florida United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
SBIR Details
Research Type
STTR Phase I
Title
STTR Phase I:Steroid-eluting thread for the treatment of rhinitis
Abstract
The broader impact/commercial potential of this this Small Business Technology Transfer (STTR) Phase I project is a novel, minimally invasive, surgical option for reducing complications and improving outcomes for rhinitis patients. A bioabsorbable, steroid-eluting suture and surgical implant procedure will be developed to improve outcomes for 6 million patients suffering from rhinitis under the care of otolaryngologists, or ear, nose and throat specialists. The proposed suture system and surgical suite implant procedure enables a temporary therapy that replaces the need for current chronic, daily, topical sprays and/or long-term immunotherapy with a single in-office visit. The bioabsorbable, drug-eluting platform also provides potential extensibility for eluting other medications including antibiotic and antifungal therapies. _x000D_ _x000D_ This Small Business Technology Transfer Phase I project aims to deliver a prototype steroid-eluting dissolvable thread with an introducing surgical tool. The project is comprised of several steps including the formulation of dissolvable polymers, and prototyping using Hot Melt Extrusion (HME). This effort will advance the platform design and development of optimized drug-elution thread for use in the nasal cavity. The system will be designed using the preferred steroid of mometasone furoate and characterized for drug elution properties in a preclinical animal model._x000D_ _x000D_ This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
MD
Solicitation Number
NSF 22-551
Status
(Complete)
Last Modified 9/22/23
Period of Performance
9/15/23
Start Date
8/31/24
End Date
Funding Split
$255.0K
Federal Obligation
$0.0
Non-Federal Obligation
$255.0K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2305502
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
FXSHAPWAFFJ6
Awardee CAGE
95RX5
Performance District
FL-05
Senators
Marco Rubio
Rick Scott
Rick Scott
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Research and Related Activities, National Science Foundation (049-0100) | General science and basic research | Grants, subsidies, and contributions (41.0) | $255,045 | 100% |
Modified: 9/22/23